Diamyd_logo
Diamyd US Phase III Study In Progress
Diamyd Medical announced it has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd or placebo...
xoma-logo
Two New Patents Issued to XOMA for Diabetes Drug
The California based bio-tech company XOMA announced that the U.S. Patent and Trademark Office has issued two new patents to XOMA as part of the company's expanding intellectual property portfolio around its XOMA 052 antibody to interleukin-1 beta (IL-1 beta)...
Nazi Nightmare or Hypoglycemia?
I had a very scary night last night. It started out like most nights, nothing unusual.  I checked my blood sugar before eating dinner, it was 130,  …
PositiveID - logo
Voxiva Inc. and PositiveID Partner to Offer an Integrated Mobile Diabetes Solution
Voxiva Inc. and PositiveID Corporation, announced that they are integrating PositiveID's wireless iglucose system with Voxiva's care4life diabetes management program. This will create an innovative, end-to-end wireless diabetes management solution, which the companies will showcase together at the mHealth Summit in Washington, DC on November 8-10...
Help Take Diabetes Out of the Closet
November 1st ushers in Diabetes Month. Diabetes organizations are in full swing to raise public awareness about this preventable disease, spreading…
Bristol-Myers Logo
KOMBIGLYZE XR Approved for the Treatment of Type 2 Diabetes
Bristol-Myers Squibb Company and AstraZeneca announced FDA approval of KOMBIGLYZE™ XR, the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR offers...